Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMPACT: Certolizumab Pegol in Psoriasis
NCT02346240Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2015
- Primary completion
- Mar 2016
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 9
01
Overview
A Phase 3 trial of certolizumab pegol in plaque psoriasis, sponsored by UCB. Started Feb 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02346240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346240.